131 related articles for article (PubMed ID: 34795098)
1. Challenges and Experiences Extending the cBioPortal for Cancer Genomics to a Molecular Tumor Board Platform.
Reimer N; Unberath P; Busch H; Börries M; Metzger P; Ustjanzew A; Renner C; Prokosch HU; Christoph J
Stud Health Technol Inform; 2021 Nov; 287():139-143. PubMed ID: 34795098
[TBL] [Abstract][Full Text] [Related]
2. Extending cBioPortal for Therapy Recommendation Documentation in Molecular Tumor Boards: Development and Usability Study.
Renner C; Reimer N; Christoph J; Busch H; Metzger P; Boerries M; Ustjanzew A; Boehm D; Unberath P
JMIR Med Inform; 2023 Dec; 11():e50017. PubMed ID: 38079196
[TBL] [Abstract][Full Text] [Related]
3. Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal.
Buechner P; Hinderer M; Unberath P; Metzger P; Boeker M; Acker T; Haller F; Mack E; Nowak D; Paret C; Schanze D; von Bubnoff N; Wagner S; Busch H; Boerries M; Christoph J
Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32050609
[TBL] [Abstract][Full Text] [Related]
4. Developing New Analysis Functions for a Translational Research Platform: Extending the cBioPortal for Cancer Genomics.
Unberath P; Knell C; Prokosch HU; Christoph J
Stud Health Technol Inform; 2019; 258():46-50. PubMed ID: 30942711
[TBL] [Abstract][Full Text] [Related]
5. FhirSpark - Implementing a Mediation Layer to Bring FHIR to the cBioPortal for Cancer Genomics.
Reimer N; Unberath P; Busch H; Ingenerf J
Stud Health Technol Inform; 2021 May; 281():303-307. PubMed ID: 34042754
[TBL] [Abstract][Full Text] [Related]
6. cbpManager: a web application to streamline the integration of clinical and genomic data in cBioPortal to support the Molecular Tumor Board.
Ustjanzew A; Desuki A; Ritzel C; Dolezilek AC; Wagner DC; Christoph J; Unberath P; Kindler T; Faber J; Marini F; Panholzer T; Paret C
BMC Med Inform Decis Mak; 2021 Dec; 21(1):358. PubMed ID: 34930224
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
[TBL] [Abstract][Full Text] [Related]
8. Molecular Tumor Boards: current practice and future needs.
van der Velden DL; van Herpen CML; van Laarhoven HWM; Smit EF; Groen HJM; Willems SM; Nederlof PM; Langenberg MHG; Cuppen E; Sleijfer S; Steeghs N; Voest EE
Ann Oncol; 2017 Dec; 28(12):3070-3075. PubMed ID: 29045504
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards.
Love TM; Anaya DA; Prime MS; Ardolino L; Ekinci O
PLoS One; 2022; 17(5):e0268477. PubMed ID: 35560035
[TBL] [Abstract][Full Text] [Related]
10. Automatic Integration of Clinical and Genetic Data Using cBioPortal.
Brunner M; Mullen L; Jauk F; Oliver J; Cayol F; Minata J; Herrera V; Pavicic W; Luna D; Risk M; Garcia Rivello H; Benitez S
Stud Health Technol Inform; 2022 Jun; 290():799-803. PubMed ID: 35673128
[TBL] [Abstract][Full Text] [Related]
11. openEHR Mapper - A Tool to Fuse Clinical and Genomic Data Using the openEHR Standard.
Reimer N; Ulrich H; Busch H; Kock-Schoppenhauer AK; Ingenerf J
Stud Health Technol Inform; 2021 May; 278():86-93. PubMed ID: 34042880
[TBL] [Abstract][Full Text] [Related]
12. Searching of Clinical Trials Made Easier in cBioPortal Using Patients' Genetic and Clinical Profiles.
Unberath P; Mahlmeister L; Reimer N; Busch H; Boerries M; Christoph J
Appl Clin Inform; 2022 Mar; 13(2):363-369. PubMed ID: 35354211
[TBL] [Abstract][Full Text] [Related]
13. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal.
de Bruijn I; Kundra R; Mastrogiacomo B; Tran TN; Sikina L; Mazor T; Li X; Ochoa A; Zhao G; Lai B; Abeshouse A; Baiceanu D; Ciftci E; Dogrusoz U; Dufilie A; Erkoc Z; Garcia Lara E; Fu Z; Gross B; Haynes C; Heath A; Higgins D; Jagannathan P; Kalletla K; Kumari P; Lindsay J; Lisman A; Leenknegt B; Lukasse P; Madela D; Madupuri R; van Nierop P; Plantalech O; Quach J; Resnick AC; Rodenburg SYA; Satravada BA; Schaeffer F; Sheridan R; Singh J; Sirohi R; Sumer SO; van Hagen S; Wang A; Wilson M; Zhang H; Zhu K; Rusk N; Brown S; Lavery JA; Panageas KS; Rudolph JE; LeNoue-Newton ML; Warner JL; Guo X; Hunter-Zinck H; Yu TV; Pilai S; Nichols C; Gardos SM; Philip J; ; Kehl KL; Riely GJ; Schrag D; Lee J; Fiandalo MV; Sweeney SM; Pugh TJ; Sander C; Cerami E; Gao J; Schultz N
Cancer Res; 2023 Dec; 83(23):3861-3867. PubMed ID: 37668528
[TBL] [Abstract][Full Text] [Related]
14. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
15. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL
JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684
[TBL] [Abstract][Full Text] [Related]
16. Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
Willemsen AECAB; Krausz S; Ligtenberg MJL; Grünberg K; Groen HJM; Voest EE; Cuppen EPJG; van Laarhoven HWM; van Herpen CML
Br J Cancer; 2019 Jul; 121(1):34-36. PubMed ID: 31130724
[TBL] [Abstract][Full Text] [Related]
17. Genomic expertise in action: molecular tumour boards and decision-making in precision oncology.
Bourret P; Cambrosio A
Sociol Health Illn; 2019 Nov; 41(8):1568-1584. PubMed ID: 31197873
[TBL] [Abstract][Full Text] [Related]
18. Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.
Liu A; Vicenzi P; Sharma I; Orr K; Teller C; Koentz M; Trinkman H; Vallance K; Ray A
Hematol Rep; 2023 Apr; 15(2):244-255. PubMed ID: 37092519
[TBL] [Abstract][Full Text] [Related]
19. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G; Canfora M; Terrenato I; Agnoletto C; Agustoni F; Amoroso L; Baldassarre G; Curigliano G; Delmonte A; De Luca A; Fiorentino M; Gregorc V; Ibrahim T; Lazzari C; Mastronuzzi A; Pronzato P; Santoro A; Scambia G; Tommasi S; Vingiani A; Giacomini P; De Maria R
J Exp Clin Cancer Res; 2022 Oct; 41(1):305. PubMed ID: 36245005
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards.
Crimini E; Repetto M; Tarantino P; Ascione L; Antonarelli G; Rocco EG; Barberis M; Mazzarella L; Curigliano G
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
